---
author: mike
pubDatetime: 2024-04-30 09:25:21.409000
modDatetime: 
title: Q124 RVTY earnings
slug: q124-rvty-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
- transcripts
- earnings
- healthcare
description: Earnings summary for Q124 Revvity
---

### Earnings Results
- **Revenue**: Q1 2024 reported total adjusted revenues of $650 million, with a 3% decline in organic revenue.
- **Operating Margins**: Adjusted operating margins reached 25.5%, approximately 100 basis points above expectations.
- **Free Cash Flow**: Generated over $130 million of free cash flow for the second consecutive quarter.
- **Adjusted EPS**: For the first quarter, adjusted EPS was $0.98, $0.05 above the midpoint of expectations.

### Future Guidance
- **Revenue Forecast**: Full year revenue expected to be in the range of $2.76 billion to $2.82 billion, adjusting for previously anticipated FX tailwinds now seen as neutral.
- **Organic Growth**: Organic growth projected in the 1% to 3% range for the full year.
- **Operating Margins**: Full year operating margins anticipated to hold roughly flat at 28%.
- **Adjusted EPS Guidance**: Maintained for the full year in the range of $4.55 to $4.75, despite the first quarter's outperformance being offset by FX headwinds.

### Trends, Market Conditions, Sentiment
- **Market Stabilization**: While the market has stabilized, pharma and biotech spending has been slower to pick up, affecting orders and causing a cautious outlook.
- **Segment Performance**: Diagnostic businesses and software offerings showed robust performance and growth, offsetting declines in the Life Sciences and Applied Genomics segments.
- **Strategic Realignment**: The management realignment and focus on operational efficiency are aimed at bolstering internal collaboration and driving innovation.
- **Cost Management**: Continued efforts in eliminating stranded costs and optimizing operations to weather softer market conditions and potentially improve margins.
- **Cash Flow Focus**: Strong emphasis on improving cash flows through better management of purchasing, inventory, and spending.
- **China Market**: Mixed results in China, with revenue overall declining mid-single digits but showing pockets of growth in Immunodiagnostics.
- **Capital Deployment**: Active in repurchasing shares and evaluating potential acquisitions, maintaining a strategic focus on cash and balance sheet management.

### Notable Quotes
- **Prahlad Singh**: "We are making more profound advancement in our operating structure and our go-to-market strategy, which will both enable us to properly weather the current industry environment as well as set us up to accelerate our financial performance."
- **Maxwell Krakowiak**: "The company has performed well over the first several months of 2024 despite a continued challenging end market...These focus areas really performing well in the first quarter, with our adjusted operating margins of 25.5% being approximately 100 basis points above our expectations, and our $132 million of free cash flow being well over 100% of our adjusted net income in the quarter."
- **Prahlad Singh on rebranding and divestiture activities**: "Now that we are almost at 1 year since becoming Revvity...I see every day how the company is beginning to hit its stride."
